Horowitz M, Maddern G J, Maddox A, Wishart J, Chatterton B E, Shearman D J
Gastroenterology. 1987 Aug;93(2):311-5. doi: 10.1016/0016-5085(87)91020-1.
The effects of cisapride on gastric emptying, esophageal emptying, and gastrointestinal symptoms were evaluated in 8 patients with progressive systemic sclerosis who had delayed gastric emptying of the solid or liquid component of a meal, or both. A double-isotope technique was used to measure gastric emptying, and esophageal emptying was measured as the time for a bolus of the solid meal to enter the stomach. Gastrointestinal symptoms were assessed by a questionnaire. On 2 days each patient received cisapride (10 mg) or placebo intravenously, 5 min before an esophageal and gastric emptying test. After these 2 days each subject took cisapride (10 mg q.i.d., p.o.) for 1 mo. Cisapride improved solid and liquid gastric emptying (p less than 0.001), but had no significant effect on esophageal emptying (p less than 0.1). Upper gastrointestinal symptoms were reduced after cisapride (p less than 0.001), and no side effects were reported. These results indicate that gastroparesis is a treatable cause of morbidity in progressive systemic sclerosis.
在8例进行性系统性硬化症患者中评估了西沙必利对胃排空、食管排空及胃肠道症状的影响，这些患者存在进餐固体或液体成分胃排空延迟，或两者均延迟的情况。采用双同位素技术测量胃排空，食管排空则通过固体餐团进入胃的时间来测量。通过问卷调查评估胃肠道症状。在进行食管和胃排空试验前5分钟，每位患者在2天内每天静脉接受西沙必利（10毫克）或安慰剂。这2天后，每位受试者口服西沙必利（10毫克，每日4次），持续1个月。西沙必利改善了固体和液体胃排空（p<0.001），但对食管排空无显著影响（p<0.1）。西沙必利治疗后上消化道症状减轻（p<0.001），且未报告有副作用。这些结果表明，胃轻瘫是进行性系统性硬化症发病的一个可治疗原因。
